IRIS
TALAMONTI, MARINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.257
EU - Europa 1.238
AS - Asia 936
SA - Sud America 10
Continente sconosciuto - Info sul continente non disponibili 8
OC - Oceania 4
AF - Africa 1
Totale 15.454
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.243
SG - Singapore 523
IE - Irlanda 297
CN - Cina 269
IT - Italia 190
RU - Federazione Russa 159
DE - Germania 157
UA - Ucraina 115
SE - Svezia 89
GB - Regno Unito 67
FR - Francia 64
KR - Corea 44
FI - Finlandia 34
IN - India 21
ID - Indonesia 17
PL - Polonia 14
CA - Canada 11
KG - Kirghizistan 11
ES - Italia 9
NL - Olanda 9
HK - Hong Kong 8
BE - Belgio 7
BR - Brasile 6
EU - Europa 6
JP - Giappone 6
MY - Malesia 6
UZ - Uzbekistan 6
CZ - Repubblica Ceca 5
AU - Australia 4
CH - Svizzera 4
CL - Cile 4
GR - Grecia 4
IL - Israele 4
PH - Filippine 4
TR - Turchia 4
AT - Austria 3
BD - Bangladesh 3
RO - Romania 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
DK - Danimarca 2
MX - Messico 2
SI - Slovenia 2
VN - Vietnam 2
EG - Egitto 1
HU - Ungheria 1
IR - Iran 1
JO - Giordania 1
KZ - Kazakistan 1
MD - Moldavia 1
MN - Mongolia 1
NO - Norvegia 1
PA - Panama 1
RS - Serbia 1
TH - Thailandia 1
Totale 15.454
Salva come PNG Salva come JPEG
Città #
Wilmington 3.382
Houston 3.220
Woodbridge 2.182
Fairfield 872
Chandler 510
Ashburn 499
Singapore 439
Seattle 391
Cambridge 307
Ann Arbor 301
Dublin 280
Medford 210
Beijing 120
Santa Clara 109
Dearborn 102
Lawrence 101
Jacksonville 80
San Diego 63
New York 48
Moscow 45
Rome 44
Munich 39
Zhengzhou 30
Redwood City 24
London 23
Shanghai 20
Menlo Park 18
Jakarta 17
Seoul 17
Council Bluffs 16
Boardman 14
Falls Church 14
Kraków 14
Esslingen am Neckar 13
Milan 13
Pune 13
Norwalk 12
Helsinki 11
Mountain View 10
Guangzhou 9
Los Angeles 9
Saint Petersburg 9
Del Norte 8
Hefei 8
Hong Kong 8
Perugia 8
Brussels 7
Mülheim 7
Ottawa 7
Detroit 6
Nanchang 6
Nanjing 6
San Mateo 6
Brno 5
Frosinone 5
Palo Alto 5
Putrajaya 5
Chengdu 4
Engelhard 4
Espoo 4
Kilburn 4
Manila 4
Nuremberg 4
Renton 4
Washington 4
Bochum 3
Casarile 3
Coushatta 3
Hebei 3
Hyderabad 3
Islington 3
Jinan 3
Lausanne 3
Madrid 3
Rapallo 3
Salt Lake City 3
San Giorgio di Nogaro 3
São Paulo 3
Toronto 3
Valencia 3
Wandsworth 3
Wuhan 3
Augusta 2
Berlin 2
Bologna 2
Chions 2
Clearwater 2
Croydon 2
Dhaka 2
Dong Ket 2
General Escobedo 2
Giugliano In Campania 2
Jinhua 2
Kunming 2
Melbourne 2
Memphis 2
Monte Vista 2
Pescara 2
Phoenix 2
Piombino Dese 2
Totale 13.866
Salva come PNG Salva come JPEG
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 448
Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. 443
Evaluation of clinical and ultrasonographic parameters in psoriatic arthritis patients treated with adalimumab: a retrospective study 398
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 392
Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy 391
Continuous treatment of plaque-type psoriasis with etanercept: An observational long-term experience 389
Tildrakizumab for treating psoriasis 387
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 385
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics 384
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 371
Brodalumab for the treatment of psoriasis 369
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 367
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 362
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 360
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 359
Tofacitinib for the treatment of psoriasis 351
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 342
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 333
A safety evaluation of guselkumab for the treatment of psoriasis 311
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 303
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 296
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 282
Photo-recall cutaneous reaction to gemcitabine 273
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 272
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 269
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 268
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 252
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 246
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 241
Pharmacotherapeutic management of psoriasis in adolescents and children 233
Skin immunity and its dysregulation in psoriasis 223
Successful treatment of psoriatic crumbly nails with ustekinumab 212
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 207
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 201
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 192
Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life 186
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 172
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 166
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 163
Erythrodermic psoriasis treated with ustekinumab: An Italian multicenter retrospective analysis 159
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 141
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab 140
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers 135
Latent tuberculosis infection in patients with chronic plaque psoriasis: Evidence from the Italian Psocare Registry 134
Long-term treatment of plaque psoriasis with efalizumab: an Italian experience 123
Detection of adalimumab and anti-adalimumab levels by ELISA: clinical considerations 117
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 111
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 105
Patients with moderate to severe plaque psoriasis: One year after the European medicines agency recommendation of efalizumab suspension 105
Efalizumab 100
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 99
Genetic markers predictive of clinical response to biological drugs in psoriasis. 89
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 86
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 83
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 73
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 73
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 72
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 71
Italian guidelines in diagnosis and treatment of alopecia areata 70
Bullous pemphigoid: Italian guidelines adapted from the EDF/EADV guidelines 70
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 70
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 69
Adalimumab for moderate to severe psoriasis: an open-label, retrospective 3-year study 68
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 67
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 67
HLA-Cw6 allele confers sensitivity to efalizumab treatment in psoriasis 63
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 62
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 60
Long-term efficacy of adalimumab in generalized pustular psoriasis 56
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 54
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 54
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 53
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 53
Clinical severity instruments 51
Linear psoriasis following the typical distribution of the sciatic nerve 50
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 48
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 48
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 47
Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: Results from the Italian Psocare Registry 46
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 45
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 45
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients 44
Guselkumab: an anti-IL-23 antibody for the treatment of moderate-to-severe plaque psoriasis 43
Next generation sequencing technology to explore anti-inflammatory activity of IKKa in psoriasis 42
Italian Guidelines in Pemphigus - adapted from the European Dermatology Forum (EDF) and European Academy of Dermatology and Venerology (EADV) 42
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis 42
Genetic variations in IL6 and IL12B as protective markers for psoriasis 42
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes Abstracts of the 4th Congress of the Psoriasis International Network. July 4-6, 2013. Paris, France 39
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 39
Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics 38
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 38
A real-world economic analysis of biologic therapies for moderate-to-severe plaque psoriasis in Italy: results of the CANOVA observational longitudinal study 37
Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom 34
Pruritus characteristics in a large Italian cohort of psoriatic patients 34
Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry 34
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 33
Secukinumab improves patient perception of anxiety and depression in patients with moderate to severe psoriasis: a post hoc analysis of the SUPREME study 33
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 32
Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients 29
A phase II study of ponesimod in chronic plaque psoriasis: improvements in patient-reported outcomes 29
Totale 15.835
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.742
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.742
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.907 0 0 0 0 0 459 380 384 502 546 336 300
2020/20213.515 331 347 325 385 418 506 401 344 118 166 124 50
2021/20221.134 65 101 107 35 29 52 139 42 84 87 84 309
2022/20231.216 142 125 104 117 78 299 91 61 102 21 45 31
2023/2024524 41 14 22 13 65 121 68 64 4 8 27 77
2024/20251.184 121 453 268 238 33 71 0 0 0 0 0 0
Totale 16.103